CD83

Across TCGA pan-cancer cohorts, CD83 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD83 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CD83 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD83 expression acts as an unfavorable survival marker.

SCLC, LIHC, and ACC are the cancer types where CD83 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LIHC	DFS	Median	All	0.038	0.553	<.001	9	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD83–SCLC (OS)

Open the SCLC breakdown →